VA/DoD CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction Provider Summary Table of Contents Scope of the CPG 1 A. Populations Included in this Guideline 1 B. Populations Excluded from this Guideline 1 Algorithm: Management of Dyslipidemia for Cardiovascular Risk Reduction 6 Statin and Non-statin Pharmacologic Agents 8 Guideline Work Group 9 Patient-centered Care 10 Shared Decision Making 11 References 11 VA/DoD CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction Provider Summary Introduction The Department of Veterans Affairs (VA) and Department of Defense (DoD) Evidence-Based Practice Work Group (EBPWG) was established and first chartered in 2004, with a mission to advise the Health Executive Committee (HEC) on the use of clinical and epidemiological evidence to improve the health of the population across the Veterans Health Administration (VHA) and Military Health System (MHS), by facilitating the development of clinical practice guidelines (CPGs) for the VA and DoD populations.[1] This CPG is intended to provide healthcare providers with a framework by which to evaluate, treat, and manage the individual needs and preferences of patients with dyslipidemia, thereby leading to improved clinical outcomes. In 2014, the VA and DoD published a CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction (2014 VA/DoD Dyslipidemia CPG), which was based on evidence reviewed from January 2010 through February 2014. Since then, a growing body of research has expanded the general knowledge and understanding of dyslipidemia and cardiovascular (CV) risk. A recommendation to update the 2014 VA/DoD Dyslipidemia CPG was initiated in 2019. The system-wide goal of evidence-based guidelines is to improve the patient s health and well-being. To that end, this CPG is intended to guide providers who care for patients with dyslipidemia along management pathways supported by evidence. 